Concise Review: Stem Cells and Epithelial-Mesenchymal Transition in Cancer: Biological Implications and Therapeutic Targets

Stem Cells

Volumn 34, Issue 8, 2016, Pages 1997-2007

  Sato, Ryo ^a,b   Semba, Takashi ^a,b   Saya, Hideyuki ^a   Arima, Yoshimi ^a  

^a KEIO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Cancer stem cell; Epithelial mesenchymal transition; Therapeutic resistance; Tumor heterogeneity

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL HETEROGENEITY; CELL PLASTICITY; CLONAL EVOLUTION; DAUGHTER CELL; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; HUMAN; NEOPLASM; UPREGULATION;

EID: 84982861778     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2406     Document Type: Article

References (159)

1. Burrell RA, McGranahan N, Bartek J et al. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501:338–345.
2. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell 2014;14:275–291.
3. Strauss R, Li ZY, Liu Y et al. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One 2011;6:e16186.
4. Huang RY, Wong MK, Tan TZ et al. An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis 2013;4:e915.
5. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells–perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006;66:9339–9344.
6. Wicha MS, Liu S Dontu G. Cancer stem cells: An old idea–a paradigm shift. Cancer Res 2006;66:1883–1890.
7. Bonnet D Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;7:730–737.
8. Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983–3988.
9. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821–5828.
10. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111–115.
11. Eramo A, Lotti F, Sette G et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:504–514.
12. Patrawala L, Calhoun T, Schneider-Broussard R et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696–1708.
13. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030–1037.
14. Sugihara E Saya H. Complexity of cancer stem cells. Int J Cancer 2013;132:1249–1259.
15. Wang J, Sakariassen PØ, Tsinkalovsky O et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008;122:761–768.
16. Zhang S, Balch C, Chan MW et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008;68:4311–4320.
17. Stewart JM, Shaw PA, Gedye C et al. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci USA 2011;108:6468–6473.
18. Ng JM Curran T. The Hedgehog's tale: Developing strategies for targeting cancer. Nat Rev Cancer 2011;11:493–501.
19. Weng AP, Ferrando AA, Lee W et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269–271.
20. Castellanos JA, Merchant NB Nagathihalli NS. Emerging targets in pancreatic cancer: Epithelial-mesenchymal transition and cancer stem cells. Onco Targets Ther 2013;6:1261–1267.
21. Borah A, Raveendran S, Rochani A et al. Targeting self-renewal pathways in cancer stem cells: Clinical implications for cancer therapy. Oncogenesis 2015;4:e177.
22. Takahashi-Yanaga F Kahn M. Targeting wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010;16:3153–3162.
23. Vermeulen L, De Sousa E Melo F, van der Heijden M et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010;12:468–476.
24. Sakaki-Yumoto M, Katsuno Y Derynck R. TGF-β family signaling in stem cells. Biochim Biophys Acta 2013;1830:2280–2296.
25. Tata PR, Mou H, Pardo-Saganta A et al. Dedifferentiation of committed epithelial cells into stem cells in vivo. Nature 2013;503:218–223.
26. Roesch A, Fukunaga-Kalabis M, Schmidt EC et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010;141:583–594.
27. Suvà ML, Rheinbay E, Gillespie SM et al. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 2014;157:580–594.
28. Oshima N, Yamada Y, Nagayama S et al. Induction of cancer stem cell properties in colon cancer cells by defined factors. PLoS One 2014;9:e101735.
29. Chang C-J, Yang J-Y, Xia W et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell 2011;19:86–100.
30. Abdouh M, Facchino S, Chatoo W et al. BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci 2009;29:8884–8896.
31. Chen W-J, Ho C-C, Chang Y-L et al. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat Commun 2014;5:3472.
32. Charles N, Ozawa T, Squatrito M et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 2010;6:141–152.
33. Philip B, Ito K, Moreno-Sánchez R et al. HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression. Carcinogenesis 2013;34:1699–1707.
34. Anderson K, Lutz C, van Delft FW et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011;469:356–361.
35. Odoux C, Fohrer H, Hoppo T et al. A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res 2008;68:6932–6941.
36. Kalluri R Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420–1428.
37. Savagner P, Kusewitt DF, Carver EA et al. Developmental transcription factor slug is required for effective re-epithelialization by adult keratinocytes. J Cell Physiol 2005;202:858–866.
38. Kusewitt DF, Choi C, Newkirk KM et al. Slug/Snai2 is a downstream mediator of epidermal growth factor receptor-stimulated reepithelialization. J Invest 2009;129:491–495. Dermalol
39. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442–454.
40. Trimboli AJ, Fukino K, de Bruin A et al. Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 2008;937–945. 63:
41. Rhim AD, Mirek ET, Aiello NM et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012;148:349–361.
42. Entenberg D, Kedrin D, Wyckoff J et al. Imaging tumor cell movement in vivo. Curr Protoc Cell Biol 2013; Chapter 19:Unit19.7.
43. Nieto MA Cano A. The epithelial–mesenchymal transition under control: Global programs to regulate epithelial plasticity. Semin Cancer Biol 2012;22:361–368.
44. Nieto MA, Sargent MG, Wilkinson DG et al. Control of cell behavior during vertebrate development by Slug, a zinc finger gene. Science 1994;264:835–839.
45. De Craene B Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013;13:97–110.
46. Herranz N, Pasini D, Díaz VM et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol 2008;15:4772–4781.
47. Peinado H, Ballestar E, Esteller M et al. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol 2004;1:306–319.
48. Lin T, Ponn A, Hu X et al. Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition. Oncogene 2010;29:4896–4904.
49. Dong C, Wu Y, Yao J et al. G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J Clin Invest 2012;4:1469–1486.
50. Yang MH, Hsu DS, Wang HW et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 2010;12:982–992.
51. Li HJ, Yu PN, Huang KY et al. NKX6.1 functions as a metastatic suppressor through epigenetic regulation of the epithelial-mesenchymal transition. Oncogene 10.1038/onc.2015-289
52. Francí C, Takkunen M, Dave N et al. Expression of Snail protein in tumor-stroma interface. Oncogene 2006;25:5134–5144.
53. Peinado H, Olmeda D Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007;7:415–428.
54. Zhou BP, Deng J, Xia W et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004;10:931–940.
55. Côme C, Magnino F, Bibeau F et al. Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res 2006;12:5395–5402.
56. Martin TA, Goyal A, Watkins G et al. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol 2005;12:488–496.
57. Mock K, Preca BT, Brummer T et al. The EMT-activator ZEB1 induces bone metastasis associated genes including BMP-inhibitors. Oncotarget 2015;6:14399–14412.
58. Si W, Huang W, Zheng Y et al. Dysfunction of the reciprocal feedback loop between GATA3- and ZEB2-nucleated repression programs contributes to breast cancer Metastasis. Cancer Cell 2015;27:822–836.
59. Yang J, Mani SA, Donaher JL et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927–939.
60. Fang X, Cai Y, Liu J et al. Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal. Oncogene 2011;30:4707–4720.
61. Mao Y, Zhang N, Xu J et al. Significance of heterogeneous Twist2 expression in human breast cancers. PLoS One 2012;7:e48178.
62. Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704–715.
63. Guo W, Keckesova Z, Donaher JL et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 2012;148:1015–1028.
64. Chaffer CL, Marjanovic ND, Lee T et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013;154:61–74.
65. Wellner U, Schubert J, Burk UC et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009;11:1487–1495.
66. Liang Y, Hu J, Li J et al. Epigenetic activation of TWIST1 by MTDH promotes cancer Stem-like cell traits in breast Cancer. Cancer Res 2015;75:3672–3680.
67. Fan XJ, Wan XB, Yang ZL et al. Snail promotes lymph node metastasis and Twist enhances tumor deposit formation through epithelial-mesenchymal transition in colorectal cancer. Hum Pathol 2013;44:173–180.
68. Shioiri M, Shida T, Koda K et al. Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br J Cancer 2006;94:1816–1822.
69. Spaderna S, Schmalhofer O, Hlubek F et al. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 2006;131:830–840.
70. Kahlert C, Lahes S, Radhakrishnan P et al. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin Cancer Res 2011;17:7654–7663.
71. Hwang WL, Yang MH, Tsai ML et al. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology 2011;141:279–291.
72. Shih JY, Tsai MF, Chang TH et al. Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res 2005;11:8070–8078.
73. Miyahara S, Hamasaki M, Hamatake D et al. Clinicopathological analysis of pleomorphic carcinoma of the lung: diffuse ZEB1 expression predicts poor survival. Lung Cancer 2015;87:39–44.
74. Wang G, Dong W, Shen H et al. A comparison of Twist and E-cadherin protein expression in primary non-small-cell lung carcinoma and corresponding metastases. Eur J Cardiothorac Surg 2011;39:1028–1032.
75. Liu CW, Li CH, Peng YJ et al. Snail regulates Nanog status during the epithelial-mesenchymal transition via the Smad1/Akt/GSK3β signaling pathway in non-small-cell lung cancer. Oncotarget 2014;5:3880–3894.
76. Yang MH, Chen CL, Chau GY et al. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology 2009;50:1464–1474.
77. Zhou YM, Cao L, Li B et al. Clinicopathological significance of ZEB1 protein in patients with hepatocellular carcinoma. Ann Surg Oncol 2012;19:1700–1706.
78. Lee TK, Poon RT, Yuen AP et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 2006;12:5369–5376.
79. Sun Y, Song GD, Sun N et al. Slug overexpression induces stemness and promotes hepatocellular carcinoma cell invasion and metastasis. Oncol Lett 2014;7:1936–1940.
80. Liu AY, Cai Y, Mao Y et al. wist2 promotes self-renewal of liver cancer stem-like cells by regulating CD24. Carcinogenesis 2014;35:537–545.
81. Yang MH, Chang SY, Chiou SH et al. Overexpression of NBS1 induces epithelial-mesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer. Oncogene 26:1459–1467. 2007;
82. Gasparotto D, Polesel J, Marzotto A et al. Overexpression of TWIST2 correlates with poor prognosis in head and neck squamous cell carcinomas. Oncotarget 2011;2:1165–1175.
83. Chen C, Wei Y, Hummel M et al. Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One 2011;6:e16466.
84. Usami Y, Satake S, Nakayama F et al. Snail-associated epithelial-mesenchymal transition promotes oesophageal squamous cell carcinoma motility and progression. J Pathol 2008;215:330–339.
85. Uchikado Y, Natsugoe S, Okumura H et al. Slug expression in the E-cadherin preserved tumors is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res 2005;11:1174–1180.
86. Yuen HF, Chan YP, Wong ML et al. Upregulation of Twist in oesophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis. J Clin Pathol 2007;60:510–514.
87. Shin NR, Jeong EH, Choi CI et al. Overexpression of Snail is associated with lymph node metastasis and poor prognosis in patients with gastric cancer. BMC Cancer 2012;12:521.
88. Okugawa Y, Toiyama Y, Tanaka K et al. Clinical significance of zinc finger E-box binding homeobox 1 (ZEB1) in human gastric cancer. J Surg Oncol 2012;106:280–285.
89. Ru GQ, Wang HJ, Xu WJ et al. Upregulation of Twist in gastric carcinoma associated with tumor invasion and poor prognosis. Pathol Oncol Res 2011;17:341–347.
90. Elloul S, Silins I, Tropé CG et al. Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch 2006;449:520–528.
91. Graham TR, Zhau HE, Odero-Marah VA et al. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2008;68:2479–2488.
92. Kwok WK, Ling MT, Lee TW et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005;65:5153–5162.
93. Scheel C, Eaton EN, Li SH et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 2011;145:926–940.
94. Pallier K, Cessot A, Côté JF et al. TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma. PLoS One 2012;7:e29954.
95. Sánchez-Tilló E, de Barrios O, Siles L et al. β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci USA 2011;108:19204–19209.
96. Arima Y, Inoue Y, Shibata T et al. Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition. Cancer Res 2008;68:5104–5112.
97. Puisieux A, Brabletz T Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 2014;16:488–494.
98. Maestro R, Dei Tos AP, Hamamori Y et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999;13:2207–2217.
99. Valsesia-Wittmann S, Magdeleine M, Dupasquier S et al. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 2004;6:625–630.
100. Ansieau S, Bastid J, Doreau A et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008;14:79–89.
101. Tran PT, Shroff EH, Burns TF et al. Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis. PLoS Genet 2012;8:e1002650.
102. Ohashi S, Natsuizaka M, Wong GS et al. Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. Cancer Res 2010;70:4174–4184.
103. David CJ, Huang YH, Chen M et al. TGF-β tumor suppression through a lethal EMT. Cell 2016;164:1015–1030.
104. Inoue A, Seidel MG, Wu W et al. Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. Cancer Cell 2002;2:279–288.
105. Kajita M, McClinic KN Wade PA. Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol Cell Biol 2004;24:7559–7566.
106. Vega S, Morales AV, Ocaña OH et al. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 2004;18:1131–1143.
107. Kudo-Saito C, Shirako H, Takeuchi T et al. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 2009;15:195–206.
108. Sánchez-Tilló E, Liu Y, de Barrios O et al. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci 2012;69:3429–3456.
109. Taube JH, Herschkowitz JI, Komurov K et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A 2010;107:15449–15454.
110. Haslehurst AM, Koti M, Dharsee M et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 2012;12:91.
111. Sayan AE, Griffiths TR, Pal R et al. SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci USA 2009;106:14884–14889.
112. Witta SE, Gemmill RM, Hirsch FR et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006;66:944–950.
113. Zhuo W, Wang Y, Zhuo X et al. Knockdown of Snail, a novel zinc finger transcription factor, via RNA interference increases A549 cell sensitivity to cisplatin via JNK/mitochondrial pathway. Lung Cancer 2008;62:8–14.
114. Corcoran RB, Cheng KA, Hata AN et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013;23:121–128.
115. Singh A, Greninger P, Rhodes D et al. A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell 2009;15:489–500.
116. Yang Y, Ahn YH, Chen Y et al. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest 2014;124:2696–2708.
117. Villarejo A, Cortés-Cabrera A, Molina-Ortíz P et al. Differential role of Snail1 and Snail2 zinc fingers in E-cadherin repression and epithelial to mesenchymal transition. J Biol Chem 2014;289:930–941.
118. Caramel J, Papadogeorgakis E, Hill L et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell 2013;24:466–480.
119. Chang TH, Tsai MF, Su KY et al. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med 2011;183:1071–1079.
120. Sarrió D, Rodriguez-Pinilla SM, Hardisson D et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008;68:989–997.
121. Honeth G, Bendahl PO, Ringnér M et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008;10:R53.
122. Chen C, Zimmermann M, Tinhofer I et al. Epithelial-to-mesenchymal transition and cancer stem(-like) cells in head and neck squamous cell carcinoma. Cancer Lett 2013;338:47–56.
123. Valastyan S Weinberg RA. Tumor metastasis: Molecular insights and evolving paradigms. Cell 2011;147:275–292.
124. Morel AP, Lièvre M, Thomas C et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008;3:e2888.
125. Luanpitpong S, Li J, Manke A et al. SLUG is required for SOX9 stabilization and functions to promote cancer stem cells and metastasis in human lung carcinoma. Oncogene 2016;35:2824–2833
126. Park IK, Qian D, Kiel M et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003;423:302–305.
127. Molofsky AV, Pardal R, Iwashita T et al. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 2003;425:962–967.
128. Lessard J Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003;423:255–260.
129. Chiba T, Miyagi S, Saraya A et al. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res 2008;68:7742–7749.
130. Kreso A, van Galen P, Pedley NM et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med 2014;20:29–36.
131. Oshimori N, Oristian D, Fuchs E. TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 2015;160:963–976.
132. Chang YW, Su YJ, Hsiao M et al. Diverse targets of β-Catenin during the epithelial-mesenchymal transition define cancer stem cells and predict disease relapse. Cancer. Res 2015;75:3398–3410.
133. Hao J, Zhang Y, Deng M et al. MicroRNA control of epithelial-mesenchymal transition in cancer stem cells. Int J Cancer 2014;135:1019–1027.
134. Bracken CP, Gregory PA, Kolesnikoff N et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008;68:7846–7854.
135. Shimono Y, Zabala M, Cho RW et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009;138:592–603.
136. Celià-Terrassa T, Meca-Cortés O, Mateo F et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest 2012;122:1849–1868.
137. Beck B, Lapouge GEL, Rorive S et al. Different levels of Twist1 regulate skin tumor initiation, stemness, and progression. Cell Stem Cell 2015;16:67–79.
138. Arnold KM, Opdenaker LM, Flynn D et al. Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer. Cancer Growth Metastasis 2015;8:1–13.
139. Brabletz T, Jung A, Reu S et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 2001;98:10356–10361.
140. Ocaña OH, Córcoles R, Fabra A et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012;22:709–724.
141. Tsai JH, Donaher JL, Murphy DA et al. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012;22:725–736.
142. Chaffer CL, Brennan JP, Slavin JL et al. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006;66:11271–11278.
143. Yae T, Tsuchihashi K, Ishimoto T et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun 2012;3:883.
144. Tsuji T, Ibaragi S, Shima K et al. Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res 2008;68:10377–10386.
145. Tsuji T, Ibaragi S Hu GF. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res 2009;69:7135–7139.
146. Frank NY, Margaryan A, Huang Y et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005;65:4320–4333.
147. Tanei T, Morimoto K, Shimazu K et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009;15:4234–4241.
148. Raha D, Wilson TR, Peng J et al. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer Res 2014;74:3579–3590.
149. Ishimoto T, Nagano O, Yae T et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc- and thereby promotes tumor Growth. Cancer Cell 2011;19:387–400.
150. Schatton T Frank MH. Antitumor immunity and cancer stem cells. Ann N Y Acad Sci 2009;1176:154–169.
151. Wang B, Wang Q, Wang Z et al. Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells. Cancer Res 2014;74:5746–5757.
152. Hermann PC, Huber SL, Herrler T et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313–323.
153. Moody SE, Perez D, Pan TC et al. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 2005;8:197–209.
154. Kaufhold S Bonavida B. Central role of Snail1 in the regulation of EMT and resistance in cancer: A target for therapeutic intervention. J Exp Clin Cancer Res 2014;33:62.
155. Arima Y, Hayashi H, Sasaki M et al. Induction of ZEB proteins by inactivation of RB protein is key determinant of mesenchymal phenotype of breast cancer. J Biol Chem 2012;287:7896–7906.
156. Ceppi P, Mudduluru G, Kumarswamy R et al. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 2010;8:1207–1216.
157. Vrba L, Jensen TJ, Garbe JC et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One 2010;5:e8697.
158. Tam WL, Lu H, Buikhuisen J et al. Protein kinase C α is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell 2013;24:347–364.
159. Shaul YD, Freinkman E, Comb WC et al. Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. Cell 2014;158:1094–1109.